Phenotypes associated with this allele

• Allele Symbol: Cyld^tm1Ref
• Allele Name: targeted mutation 1, Reinhard Fassler
• Allele ID: MGI:3714113
• Summary: 3 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Cyld^tm1Ref/Cyld^tm1Ref	B6.129-Cyld^tm1Ref	MGI:3714979
hm2	Cyld^tm1Ref/Cyld^tm1Ref	Not Specified	MGI:3761631
ht3	Cyld^tm1Ref/Cyld^+	B6.129-Cyld^tm1Ref	MGI:3714980

Genotype
MGI:3714979

hm1

• Allelic Composition: Cyld^tm1Ref/Cyld^tm1Ref
• Genetic Background: B6.129-Cyld^tm1Ref

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

increased skin papilloma incidence ( J:108769 )

• treatment of mice in 7,12-dimethylbenz(a)antracene (DMBA) followed by 12-O-tetradecanoylphorbol-13 acetate (TPA) results in tumor formation with 7-11 week latency in all mutants whereas only 50% of wild-type mice develop papillomas after 11-16 weeks

• induced homozygotes develop 7-fold more, significantly larger papillomas than control littermates

• tumors in mutants and controls have a hyperplastic squamous epithelium with no sign of malignancy

cellular

abnormal keratinocyte proliferation ( J:108769 )

• exposure of keratinocytes to small interfering RNA specific for Bcl-3 abrogates TPA-induced proliferation

increased cell proliferation ( J:108769 )

• tumors exhibit large numbers of proliferating cells above the basal layer, which is not seen in tumors from wild-type mice; however apoptosis in tumors is similar to tumors in wild-type mice

increased keratinocyte proliferation ( J:108769 )

• TPA treatment induces proliferation in isolated Cyld-null keratinocytes

integument

abnormal keratinocyte proliferation ( J:108769 )

• exposure of keratinocytes to small interfering RNA specific for Bcl-3 abrogates TPA-induced proliferation

increased keratinocyte proliferation ( J:108769 )

• TPA treatment induces proliferation in isolated Cyld-null keratinocytes

epidermal hyperplasia ( J:108769 )

• a single dose of TPA induces epidermal hyperplasia and increases keratinocyte proliferation in back skin of mutants, but even after 20 weeks of treatment no tumor formation is observed

increased skin papilloma incidence ( J:108769 )

• treatment of mice in 7,12-dimethylbenz(a)antracene (DMBA) followed by 12-O-tetradecanoylphorbol-13 acetate (TPA) results in tumor formation with 7-11 week latency in all mutants whereas only 50% of wild-type mice develop papillomas after 11-16 weeks

• induced homozygotes develop 7-fold more, significantly larger papillomas than control littermates

• tumors in mutants and controls have a hyperplastic squamous epithelium with no sign of malignancy

Genotype
MGI:3761631

hm2

• Allelic Composition: Cyld^tm1Ref/Cyld^tm1Ref
• Genetic Background: Not Specified

immune system

immune system phenotype ( J:126113 )

N • B cell development and the number of B cells are normal

Genotype
MGI:3714980

ht3

• Allelic Composition: Cyld^tm1Ref/Cyld⁺
• Genetic Background: B6.129-Cyld^tm1Ref

neoplasm

increased skin papilloma incidence ( J:108769 )

• tumor frequency and growth is intermediate between that of tumors in Cyld homozygotes and wild-type mice

integument

increased skin papilloma incidence ( J:108769 )

• tumor frequency and growth is intermediate between that of tumors in Cyld homozygotes and wild-type mice